Conventional insulin is formulated as hexamers, an inactive form that must dissociate before becoming active. This creates a delay in onset and variability in response.
Metabulin is engineered to remain stable as monomeric, the active form of insulin, eliminating the need for dissociation and enabling immediate biological activity.
Stable in storage. Active on arrival.
The insulin receptor recognizes and binds only monomeric insulin. Hexamers are biologically inert until they fully dissociate.
Metabulin is stable in monomeric form, skipping the dissociation step that conventional insulin must undergo at the injection site.
Because Metabulin is already in the active form, receptor engagement can begin immediately upon absorption, enabling a faster, more predictable response.
Breaking a 100-year-old constraint in insulin biology
Fast by structure, not formulation.
| Feature | Traditional Insulin | Metabulin |
|---|---|---|
| Form | Hexamer | Monomer |
| Activation | Requires dissociation | No dissociation required |
| Stability | Medium | High |
| Onset | Delayed | Rapid |
| Variability | Higher | Lower |
| Receptor engagement | After dissociation | Immediate |
Metabulin's work is grounded in a fundamental insight into insulin's structural biology and how the same forces that cause fibril formation can be reprogrammed to achieve stable monomeric insulin.
Insulin has a fundamental instability in monomeric form: it readily self-associates into fibrils, long thread-like aggregates that are both biologically inactive and potentially immunogenic. This is why commercial insulin has historically been formulated as zinc-stabilized hexamers, which are far more resistant to aggregation.
The cost of that stability is delay. Hexamers must slowly dissociate at the injection site before insulin can become active, a process that introduces onset latency and dose-to-dose variability that patients experience every day.
By mapping the structural determinants of insulin fibril formation, Metabulin identified the precise molecular contacts responsible for aggregation. Metabulin's protein engineering approach targets these sites directly, disrupting the self-association pathway while preserving full receptor-binding competency.
The result is an insulin that is stable in monomeric form under real storage conditions, and that can engage the insulin receptor immediately upon delivery.
Reference publication: Structural basis of insulin fibrillation (PMC10881025)
Patent pending: PCT/US2024/034992
